Department of Surgery, Europe Hospitals Brussels, Brussels, Belgium.
Department of Nephrology, Europe Hospitals Brussels, Brussels, Belgium.
Acta Chir Belg. 2020 Apr;120(2):85-91. doi: 10.1080/00015458.2018.1561796. Epub 2019 Jan 11.
To report our experience of angioplasty with Lutonix (Bard Peripheral Vascular, Inc., Tempe, AZ) drug-coated balloon (DCB) for the treatment of failing arteriovenous fistulas (AVF). Retrospective, single-center analysis consisting of 14 patients treated with Lutonix paclitaxel DCBs in the period from July 2015 through April 2017. We analyzed technical success, clinical success, primary patency of the target lesion, primary patency of the dialysis circuit, and the rate of complications. Regular follow-up of AVF patency was realized by clinical examination and duplex ultrasonography. The Kaplan-Meier survival method was applied to determine the cumulative primary patency of the target lesion and the dialysis circuit. Technical success was 100% and clinical success 92.9%. There were no major or minor complications. Cumulative target lesion primary patency after DCB was 69.2% at 6 months and 31.6% at 12 months. Cumulative vascular circuit primary patency was 61.5% at 6 months and 31.6% at 12 months. Compared to results reported in literature with plain old balloon angioplasty (POBA), Lutonix paclitaxel DCB angioplasty proved a short-term patency benefit in treatment of dialysis AVF stenosis.
报告我们使用 Lutonix（Bard Peripheral Vascular，Inc.，Tempe，AZ）紫杉醇药物涂层球囊（DCB）治疗失功动静脉瘘（AVF）的经验。回顾性分析了 2015 年 7 月至 2017 年 4 月期间 14 例接受 Lutonix 紫杉醇 DCB 治疗的患者。我们分析了技术成功率、临床成功率、靶病变的一期通畅率、透析回路的一期通畅率和并发症发生率。通过临床检查和双功能超声定期随访 AVF 通畅情况。应用 Kaplan-Meier 生存法确定靶病变和透析回路的累积一期通畅率。技术成功率为 100%，临床成功率为 92.9%。无重大或轻微并发症。DCB 后靶病变一期通畅率 6 个月时为 69.2%，12 个月时为 31.6%。血管回路一期通畅率 6 个月时为 61.5%，12 个月时为 31.6%。与普通球囊血管成形术（POBA）的文献报道结果相比，Lutonix 紫杉醇 DCB 血管成形术在治疗透析 AVF 狭窄方面显示出短期通畅获益。
